TORONTO, Aug. 3, 2022 /CNW/ – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FSE: 4960), a leader in the treatment and research of mental health conditions, is pleased to announce it has acquired 100% of the issued and outstanding stock of KetaMD, Inc. (“KetaMD”) (the “Transaction”). KetaMD is a U.S. based, privately-held, innovative telemedicine company…


Previous articleIncannex Engages Curia to Scale-up Manufacture of cGMP IHL-216A
Next articleAlgernon Pharmaceuticals Invited to Present Phase 2 IPF and Chronic Cough Study Data at 9th American Cough Conference